<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:16:02Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10067502" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10067502</identifier>
        <datestamp>2023-04-04</datestamp>
        <setSpec>cachex</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jcsm13191" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Cachexia Sarcopenia Muscle</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Cachexia Sarcopenia Muscle</journal-id>
              <journal-id journal-id-type="doi">10.1007/13539.2190-6009</journal-id>
              <journal-id journal-id-type="publisher-id">JCSM</journal-id>
              <journal-title-group>
                <journal-title>Journal of Cachexia, Sarcopenia and Muscle</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2190-5991</issn>
              <issn pub-type="epub">2190-6009</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10067502</article-id>
              <article-id pub-id-type="pmcid">PMC10067502</article-id>
              <article-id pub-id-type="pmc-uid">10067502</article-id>
              <article-id pub-id-type="pmid">36860137</article-id>
              <article-id pub-id-type="pmid">36860137</article-id>
              <article-id pub-id-type="doi">10.1002/jcsm.13191</article-id>
              <article-id pub-id-type="publisher-id">JCSM13191</article-id>
              <article-id pub-id-type="other">JCSM-D-22-00212</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia</article-title>
                <alt-title alt-title-type="right-running-head">Macimorelin in cancer cachexia</alt-title>
                <alt-title alt-title-type="left-running-head">M. Herodes <italic toggle="yes">et al</italic>.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jcsm13191-cr-0001" contrib-type="author">
                  <name>
                    <surname>Herodes</surname>
                    <given-names>Megan</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9844-0375</contrib-id>
                  <xref rid="jcsm13191-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0002" contrib-type="author">
                  <name>
                    <surname>Anderson</surname>
                    <given-names>Lindsey J.</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0003" contrib-type="author">
                  <name>
                    <surname>Shober</surname>
                    <given-names>Samuel</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0004" contrib-type="author">
                  <name>
                    <surname>Schur</surname>
                    <given-names>Ellen A.</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0005" contrib-type="author">
                  <name>
                    <surname>Graf</surname>
                    <given-names>Solomon A.</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0006" contrib-type="author">
                  <name>
                    <surname>Ammer</surname>
                    <given-names>Nicola</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0007" contrib-type="author">
                  <name>
                    <surname>Salas</surname>
                    <given-names>Ramiro</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0008" contrib-type="author">
                  <name>
                    <surname>Marcelli</surname>
                    <given-names>Marco</given-names>
                  </name>
                  <xref rid="jcsm13191-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="jcsm13191-cr-0009" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Garcia</surname>
                    <given-names>Jose M.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4245-1753</contrib-id>
                  <xref rid="jcsm13191-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jcsm13191-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>jose.garcia@va.gov</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jcsm13191-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Gerontology and Geriatric Medicine, School of Medicine</named-content>
                <institution>University of Washington</institution>
                <city>Seattle</city>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Geriatric Research, Education and Clinical Center</named-content>
                <institution>Veterans Affairs Puget Sound Health Care System</institution>
                <city>Seattle</city>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of General Internal Medicine, Department of Medicine</named-content>
                <institution>University of Washington</institution>
                <city>Seattle</city>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Hospital and Specialty Medicine</named-content>
                <institution>Veterans Affairs Puget Sound Health Care System</institution>
                <city>Seattle</city>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Medical Oncology, Department of Medicine</named-content>
                <institution>University of Washington</institution>
                <city>Seattle</city>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Clinical Research Division</named-content>
                <institution>Fred Hutchinson Cancer Center</institution>
                <city>Seattle</city>
                <named-content content-type="country-part">WA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Clinical Development</named-content>
                <institution>Aeterna Zentaris GmbH</institution>
                <city>Frankfurt</city>
                <country country="DE">Germany</country>
              </aff>
              <aff id="jcsm13191-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Departments of Psychiatry and Neuroscience</named-content>
                <institution>Baylor College of Medicine</institution>
                <city>Houston</city>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0009" content-type="private-address">
                <label>
                  <sup>9</sup>
                </label>
                <institution>The Menninger Clinic</institution>
                <city>Houston</city>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <named-content content-type="organisation-division">Center for Translational Research on Inflammatory Diseases</named-content>
                <institution>Michael E. DeBakey Veterans Affairs Medical Center</institution>
                <city>Houston</city>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jcsm13191-aff-0011">
                <label>
                  <sup>11</sup>
                </label>
                <named-content content-type="organisation-division">Medical Care Line, Michael E. DeBakey Veterans Affairs Medical Center; Department of Medicine, Endocrinology, Diabetes and Metabolism</named-content>
                <institution>Baylor College of Medicine</institution>
                <city>Houston</city>
                <named-content content-type="country-part">TX</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Jose M. Garcia, VA Puget Sound Health Care System, 1660 South Columbian Way (S‐182‐GRECC), Building 1, Room 815J, Seattle, WA 98108. Email: <email>jose.garcia@va.gov</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>01</day>
                <month>3</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>14</volume>
              <issue seq="150">2</issue>
              <issue-id pub-id-type="doi">10.1002/jcsm.v14.2</issue-id>
              <fpage>835</fpage>
              <lpage>846</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>05</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="received">
                  <day>01</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders-->
                <copyright-statement content-type="article-copyright">© 2023 Aeterna Zentaris GmbH. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley &amp; Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JCSM-14-835.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="jcsm13191-sec-0001">
                  <title>Background</title>
                  <p>Cancer cachexia is associated with reduced body weight, appetite and quality of life (QOL) with no approved treatments. Growth hormone secretagogues like macimorelin have potential to mitigate these effects.</p>
                </sec>
                <sec id="jcsm13191-sec-0002">
                  <title>Methods</title>
                  <p>This pilot study assessed the safety and efficacy of macimorelin for 1 week. Efficacy was defined <italic toggle="yes">a priori</italic> as 1‐week change in body weight (≥0.8 kg), plasma insulin‐like growth factor (IGF)‐1 (≥50 ng/mL) or QOL (≥15%). Secondary outcomes included food intake, appetite, functional performance, energy expenditure and safety laboratory parameters. Patients with cancer cachexia were randomized to 0.5 or 1.0 mg/kg macimorelin or placebo; outcomes were assessed non‐parametrically.</p>
                </sec>
                <sec id="jcsm13191-sec-0003">
                  <title>Results</title>
                  <p>Participants receiving at least one of either macimorelin dose were combined (<italic toggle="yes">N</italic> = 10; 100% male; median age = 65.50 ± 2.12) and compared with placebo (<italic toggle="yes">N</italic> = 5; 80% male; median age = 68.00 ± 6.19). Efficacy criteria achieved: body weight (macimorelin <italic toggle="yes">N</italic> = 2; placebo <italic toggle="yes">N</italic> = 0; <italic toggle="yes">P</italic> = 0.92); IGF‐1 (macimorelin <italic toggle="yes">N</italic> = 0; placebo <italic toggle="yes">N</italic> = 0); QOL by Anderson Symptom Assessment Scale (macimorelin <italic toggle="yes">N</italic> = 4; placebo <italic toggle="yes">N</italic> = 1; <italic toggle="yes">P</italic> = 1.00) or Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F; macimorelin <italic toggle="yes">N</italic> = 3; placebo <italic toggle="yes">N</italic> = 0; <italic toggle="yes">P</italic> = 0.50). No related serious or non‐serious adverse events were reported. In macimorelin recipients, change in FACIT‐F was directly associated with change in body weight (<italic toggle="yes">r</italic> = 0.92, <italic toggle="yes">P</italic> = 0.001), IGF‐1 (<italic toggle="yes">r</italic> = 0.80, <italic toggle="yes">P</italic> = 0.01), and caloric intake (<italic toggle="yes">r</italic> = 0.83, <italic toggle="yes">P</italic> = 0.005), and inversely associated with change in energy expenditure (<italic toggle="yes">r</italic> = −0.67, <italic toggle="yes">P</italic> = 0.05).</p>
                </sec>
                <sec id="jcsm13191-sec-0004">
                  <title>Conclusions</title>
                  <p>Daily oral macimorelin for 1 week was safe and numerically improved body weight and QOL in patients with cancer cachexia compared with placebo. Longer term administration should be evaluated for mitigation of cancer‐induced reductions in body weight, appetite and QOL in larger studies.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jcsm13191-kwd-0001">growth hormone secretagogue</kwd>
                <kwd id="jcsm13191-kwd-0002">macimorelin</kwd>
                <kwd id="jcsm13191-kwd-0003">ghrelin receptor agonist</kwd>
                <kwd id="jcsm13191-kwd-0004">cancer cachexia</kwd>
                <kwd id="jcsm13191-kwd-0005">appetite</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Aeterna Zentaris Inc</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>Puget Sound Veterans Affairs Health Care System</funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>Michael E. DeBakey Veterans Affairs Medical Center</funding-source>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>
                    <institution-wrap>
                      <institution>Veterans Affairs
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000738</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>I01CX001937</award-id>
                  <award-id>RX03245</award-id>
                  <award-id>BX002807</award-id>
                </award-group>
                <award-group id="funding-0005">
                  <funding-source>
                    <institution-wrap>
                      <institution>Congressionally Directed Medical Research Program
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000090</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>PC170059</award-id>
                </award-group>
                <award-group id="funding-0006">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01AG061558</award-id>
                  <award-id>R01CA239208</award-id>
                </award-group>
                <award-group id="funding-0007">
                  <funding-source>
                    <institution-wrap>
                      <institution>University of Washington
</institution>
                      <institution-id institution-id-type="doi">10.13039/100007812</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>DK007247</award-id>
                </award-group>
                <award-group id="funding-0008">
                  <funding-source>
                    <institution-wrap>
                      <institution>Nutrition Obesity Research Center
</institution>
                      <institution-id institution-id-type="doi">10.13039/100011073</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>DK035816</award-id>
                </award-group>
                <award-group id="funding-0009">
                  <funding-source>
                    <institution-wrap>
                      <institution>Diabetes Research Center
</institution>
                      <institution-id institution-id-type="doi">10.13039/100008116</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30 DK017047</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="4"/>
                <page-count count="12"/>
                <word-count count="4294"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>April 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.7 mode:remove_FC converted:02.04.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0001"><string-name><surname>Herodes</surname><given-names>M.</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>L. J.</given-names></string-name>, <string-name><surname>Shober</surname><given-names>S.</given-names></string-name>, <string-name><surname>Schur</surname><given-names>E. A.</given-names></string-name>, <string-name><surname>Graf</surname><given-names>S. A.</given-names></string-name>, <string-name><surname>Ammer</surname><given-names>N.</given-names></string-name>, <string-name><surname>Salas</surname><given-names>R.</given-names></string-name>, <string-name><surname>Marcelli</surname><given-names>M.</given-names></string-name>, and <string-name><surname>Garcia</surname><given-names>J. M.</given-names></string-name> (<year>2023</year>) <article-title>Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia</article-title>, <source>Journal of Cachexia, Sarcopenia and Muscle</source>, <volume>14</volume>, <fpage>835</fpage>–<lpage>846</lpage>, <pub-id pub-id-type="doi">10.1002/jcsm.13191</pub-id>
<pub-id pub-id-type="pmid">36860137</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body id="jcsm13191-body-0001">
            <sec id="jcsm13191-sec-0005">
              <title>Introduction</title>
              <p>Roughly 19.3 million people globally were diagnosed with cancer in 2020.<xref rid="jcsm13191-bib-0001" ref-type="bibr"><sup>1</sup></xref> More than half of these patients will experience unintentional weight loss due to cancer‐related changes in appetite and metabolic processes, known as cachexia<xref rid="jcsm13191-bib-0002" ref-type="bibr"><sup>2</sup></xref> with an 86% incidence of weight loss 1–2 weeks prior to cancer‐related death.<xref rid="jcsm13191-bib-0003" ref-type="bibr"><sup>3</sup></xref> Cachexia is defined as ‘an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.<xref rid="jcsm13191-bib-0004" ref-type="bibr"><sup>4</sup></xref> It is associated with catabolism in cancer and is linked to elevated resting energy expenditure (REE), decreased physical function and quality of life (QOL) and is responsible for 20% of cancer‐related deaths, particularly in those with lung, gastrointestinal, pancreatic or head and neck tumours.<xref rid="jcsm13191-bib-0005" ref-type="bibr"><sup>5</sup></xref> Cancer‐related anorexia is also induced by cancer treatments and/or symptoms like anxiety, depression and pain.<xref rid="jcsm13191-bib-0006" ref-type="bibr"><sup>6</sup></xref> Despite its relevance, cachexia is often undiagnosed and unmanaged as there are no approved treatments in the United States or Europe, and off‐label treatments like appetite stimulants are largely ineffective and can be associated with serious side effects.<xref rid="jcsm13191-bib-0007" ref-type="bibr"><sup>7</sup></xref>
</p>
              <p>The hormone ghrelin plays a key role in regulating food intake and energy homeostasis by stimulating the growth hormone secretagogue receptor‐1a (GHSR‐1a) in orexigenic neurons in the hypothalamus<xref rid="jcsm13191-bib-0008" ref-type="bibr"><sup>8</sup></xref> thereby inducing positive energy balance. Ghrelin also increases anabolism by stimulating growth hormone (GH) release from somatotroph cells in the pituitary,<xref rid="jcsm13191-bib-0009" ref-type="bibr"><sup>9</sup></xref> and by non‐GHSR‐1a‐mediated direct effects in skeletal muscle and fat.<xref rid="jcsm13191-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jcsm13191-bib-0011" ref-type="bibr"><sup>11</sup></xref> Hence, ghrelin receptor agonists, known as GH secretagogues (GHS), are promising candidates for cachexia treatment. Clinical studies using GHS have shown positive effects on appetite, body weight and body composition in healthy volunteers and in patients with cancer cachexia<xref rid="jcsm13191-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jcsm13191-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jcsm13191-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="jcsm13191-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jcsm13191-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jcsm13191-bib-0018" ref-type="bibr"><sup>18</sup></xref> and one such drug, anamorelin, has been recently approved for cachexia treatment in Japan.<xref rid="jcsm13191-bib-0019" ref-type="bibr"><sup>19</sup></xref> Macimorelin, a novel, orally active GHS with similar GHSR‐1a binding affinity as ghrelin, is well‐tolerated as a single dose in healthy volunteers and individuals at risk for pituitary dysfunction.<xref rid="jcsm13191-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jcsm13191-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jcsm13191-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="jcsm13191-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="jcsm13191-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="jcsm13191-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="jcsm13191-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="jcsm13191-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="jcsm13191-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="jcsm13191-bib-0028" ref-type="bibr"><sup>28</sup></xref> It received approval from the US Food and Drug Administration (FDA) in 2017 and European Medicines Agency (EMA) in 2019 as a single dose for adult GH deficiency (AGHD) diagnosis<xref rid="jcsm13191-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jcsm13191-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="jcsm13191-bib-0029" ref-type="bibr"><sup>29</sup></xref> but has not been examined in repeated doses or in the cancer setting.</p>
              <p>This pilot study assessed safety and efficacy of daily, oral macimorelin for 1 week in cancer cachexia via body weight, insulin‐like growth factor‐1 (IGF‐1; biomarker of GH action) and QOL; appetite/food intake, functional performance, REE and other laboratory parameters were also assessed. Our primary hypothesis was that macimorelin would be safe and well‐tolerated and improve body weight, IGF‐1 and QOL compared with placebo. We also proposed that macimorelin would improve appetite/food intake, physical function and REE, compared with placebo.</p>
            </sec>
            <sec sec-type="methods" id="jcsm13191-sec-0006">
              <title>Methods</title>
              <sec id="jcsm13191-sec-0007">
                <title>Study design</title>
                <p>This randomized, double‐blind, placebo‐controlled, clinical trial was initiated at the Michael E. DeBakey VA Medical Center in Houston, TX, USA, and then moved to the VA Puget Sound Health Care System in Seattle, WA, USA. A first cohort of subjects was randomized to macimorelin 0.5 mg/kg (the dose currently FDA and EMA approved for use in AGHD diagnosis, <italic toggle="yes">N</italic> = 8) or matching placebo (<italic toggle="yes">N</italic> = 5). An interim analysis by the Data Review Committee found this 0.5‐mg/kg dose to be safe but not to meet the efficacy criteria set <italic toggle="yes">a priori</italic>. Subsequently, the plan was to randomize a second cohort of subjects to macimorelin 1 mg/kg or placebo. However, the study was closed due to poor accrual after randomizing two subjects to macimorelin and none to placebo (<italic toggle="yes">Figure</italic> <xref rid="jcsm13191-fig-0002" ref-type="fig"><italic toggle="yes">2</italic></xref>). Efficacy was defined as either ≥0.8‐kg body weight gain, ≥50‐ng/mL IGF‐1 increase or ≥15% QOL improvement, based on the observed results in a similar study in which anamorelin administered daily for 3 days significantly increased body weight in cancer cachexia patients by 0.77 kg, IGF‐1 by 54 ng/mL, and QoL by 12.5%.<xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref> Safety parameters included: complete blood count (CBC), comprehensive metabolic panel (CMP), urinalysis (UA), 12‐lead electrocardiogram (ECG) and adverse events. Study data were collected between January 2013 and October 2015.</p>
              </sec>
              <sec id="jcsm13191-sec-0008">
                <title>Participants</title>
                <p>Eligible participants were ≥18 years of age, had histological diagnosis of active malignancy, Eastern Oncology Cooperative Group (ECOG) Performance Status 0–2, cancer‐related cachexia (involuntary weight loss ≥5% over 6 months, ≥10% over 12 months or ≥2% over 6 months with body mass index [BMI] &lt;20<xref rid="jcsm13191-bib-0004" ref-type="bibr"><sup>4</sup></xref>) and were able to provide written, informed consent. Exclusion criteria: obesity (weight &gt;140 kg); recent/excessive alcohol/illicit drug use; severe depression; other conditions associated with cachexia (liver disease [aspartate/alanine transaminase {ALT/AST} &gt; three times normal upper limit], renal failure [creatinine &gt;1.5 mg/dL], untreated thyroid disease, a diagnosis of New York Heart Association Class III–IV congestive heart failure,<xref rid="jcsm13191-bib-0030" ref-type="bibr"><sup>30</sup></xref> acquired immunodeficiency syndrome, severe chronic obstructive pulmonary disease), inability to increase food intake (e.g., pain with swallowing, dysphagia, etc.); use of GH, anabolic agents or appetite stimulants; tube feeding or parenteral nutrition within 1 month; systemic corticosteroid administration for &gt;6 days/month; recent highly emetogenic chemotherapy (&lt;1 week; Hesketh scale Class 4–5); pregnant/breastfeeding or might become pregnant; co‐administration of drugs that prolong QT interval and/or induce CYP3A4; corrected QT (QTc) interval &gt;450 ms; or investigational agents.</p>
              </sec>
              <sec id="jcsm13191-sec-0009">
                <title>Study procedures</title>
                <p>Subjects underwent a screening/baseline visit and, following randomization, completed Day 1, Day 7 and post‐study visits (<italic toggle="yes">Figure</italic> <xref rid="jcsm13191-fig-0001" ref-type="fig"><italic toggle="yes">1</italic></xref>): participants fasted overnight prior to each visit. In the following order, the screening/baseline visit included medical history/physical exam (including body weight), ECG, safety (blood draw and UA; pregnancy test for females), and appetite and food intake assessment. Day 1 was completed within 24 days after screening/baseline, following completion of a 3‐day food diary in the week preceding Day 1, and included in order: medical history review/physical exam (including body weight), ECG, fasting blood draw and UA (pregnancy test for females) for safety and laboratory assessments (GH, IGF‐1, IGF binding protein‐3 [IGFBP‐3], glucose, and highly sensitive C‐reactive protein [hs‐CRP]), fasting REE, functional performance, patient‐reported QOL, study drug administration orally, blood draw one‐hour post‐dose for pharmacodynamics assessed by GH, ECG 1‐h post‐dose and post‐dose adverse events. Macimorelin was dissolved in a zero‐calorie flavoured drink (Powerade®); Powerade® alone was used as placebo by an unblinded pharmacist. Participants were provided with five doses of pre‐mixed study drug and were instructed to self‐administer one dose daily while fasting, at least 1 h before breakfast (Days 2–6). Participants were instructed to store the doses at 2–8°C and to return any unused doses on Day 7.</p>
                <fig position="float" fig-type="Figure" id="jcsm13191-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>Study flow and outcomes measures. Outline of study procedures occurring at each visit including timeframe of each visit in relation to one another and timing of procedures within each visit in relation to administration of study drug and/or test meal. <sup>a</sup>Assessed prior to and 1‐h post‐meal; <sup>b</sup>Assessed prior to and 1‐h post‐dose.</p>
                  </caption>
                  <graphic xlink:href="JCSM-14-835-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>On Day 7, participants completed the same procedures as Day 1, in addition to an appetite and food intake assessment. Study drug administration (Dose 7) took place before the test meal. One‐hour post‐dose pharmacodynamics (GH) and ECG and 1‐h post‐meal appetite rating were the last procedures. The post‐study visit occurred 11–17 days following Day 7 for a medical history review/physical exam, ECG, safety parameters (blood draw, UA; pregnancy test for females) and adverse event review.</p>
                <sec id="jcsm13191-sec-0010">
                  <title>Primary outcomes</title>
                  <p><italic toggle="yes">Efficacy:</italic> change in body weight, IGF‐1 (chemiluminescence immunoassay; standard deviation score [SDS]<xref rid="jcsm13191-bib-0031" ref-type="bibr"><sup>31</sup></xref> was also calculated), and patient‐reported QOL (Anderson Symptom Assessment Scale [ASAS]<xref rid="jcsm13191-bib-0032" ref-type="bibr"><sup>32</sup></xref> absolute score; Functional Assessment of Chronic Illness–Fatigue [FACIT‐F]<xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref> adjusted score) measured pre‐dose on Days 1 and 7; change was Day 7 − Day 1. <italic toggle="yes">Safety:</italic> CBC, CMP, UA, ECG and adverse events (National Cancer Institute Common Toxicity Criteria v4; <italic toggle="yes">Table</italic>
<xref rid="jcsm13191-tbl-0001" ref-type="table"><italic toggle="yes">1</italic></xref>).</p>
                  <table-wrap position="float" id="jcsm13191-tbl-0001" content-type="Table">
                    <label>Table 1</label>
                    <caption>
                      <p>Outcome measures and assessment</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <thead valign="bottom">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Outcome measure</th>
                          <th align="center" valign="bottom" rowspan="1" colspan="1">Description</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td colspan="2" align="left" valign="top" rowspan="1">Primary outcomes</td>
                        </tr>
                        <tr>
                          <td colspan="2" style="padding-left:10%" align="left" valign="top" rowspan="1">Efficacy</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Body weight (kg)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">A calibrated scale dedicated to this study was used to measure body weight (kg) of the participant while barefoot and wearing only a hospital gown/scrubs (and underwear, if desired) prior to dosing on Days 1 and 7.</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">IGF‐1 (ng/mL)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">
                            <p>Plasma IGF‐1 was measured while fasting prior to dosing on Days 1 and 7 using a well‐established chemiluminescence immunoassay.<xref rid="jcsm13191-bib-0024" ref-type="bibr"><sup>24</sup></xref> IGF‐1 SDS was calculated using a modification of the LMS method to correct for sex and age differences in plasma IGF‐1, using the following formula:</p>
                            <p>
                              <mml:math id="jats-math-1" display="inline" overflow="scroll">
                                <mml:mi mathvariant="italic">IGF</mml:mi>
                                <mml:mo>−</mml:mo>
                                <mml:mn>1</mml:mn>
                                <mml:mspace width="0.25em"/>
                                <mml:mi mathvariant="italic">SDS</mml:mi>
                                <mml:mo>=</mml:mo>
                                <mml:mfrac>
                                  <mml:mrow>
                                    <mml:msup>
                                      <mml:mfenced open="(" close=")">
                                        <mml:mfrac bevelled="true">
                                          <mml:mrow>
                                            <mml:mi mathvariant="italic">IGF</mml:mi>
                                            <mml:mo>−</mml:mo>
                                            <mml:mn>1</mml:mn>
                                          </mml:mrow>
                                          <mml:mi>μ</mml:mi>
                                        </mml:mfrac>
                                      </mml:mfenced>
                                      <mml:mi>λ</mml:mi>
                                    </mml:msup>
                                    <mml:mo>−</mml:mo>
                                    <mml:mn>1</mml:mn>
                                  </mml:mrow>
                                  <mml:mrow>
                                    <mml:mi>λ</mml:mi>
                                    <mml:mo>×</mml:mo>
                                    <mml:mi>σ</mml:mi>
                                  </mml:mrow>
                                </mml:mfrac>
                              </mml:math>
                            </p>
                            <p>Where IGF‐1 is the plasma IGF‐1 concentration and μ (mean), λ (lambda) and σ (standard deviation) were obtained from normative data.</p>
                          </td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">ASAS absolute score</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">This is a validated measure of quality of life (QOL) associated with symptom clusters commonly seen in cancer patient populations measured prior to dosing on Days 1 and 7</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">FACIT‐F adjusted score</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">
                            <p>This a validated measure of QOL associated with fatigue related to chronic illness measured prior to dosing on Days 1 and 7. To account for missing items, the FACIT‐F total score was adjusted by calculating the percent total score of items completed with the following:</p>
                            <p>
                              <mml:math id="jats-math-2" display="inline" overflow="scroll">
                                <mml:mfrac>
                                  <mml:mrow>
                                    <mml:mtext mathvariant="italic">FACIT</mml:mtext>
                                    <mml:mo>−</mml:mo>
                                    <mml:mi>F</mml:mi>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mtext mathvariant="italic">Total Score</mml:mtext>
                                  </mml:mrow>
                                  <mml:mrow>
                                    <mml:mi>N</mml:mi>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mtext mathvariant="italic">items completed</mml:mtext>
                                    <mml:mo>×</mml:mo>
                                    <mml:mn>4</mml:mn>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mo stretchy="true">(</mml:mo>
                                    <mml:mtext mathvariant="italic">maximum possible score for each item</mml:mtext>
                                    <mml:mspace width="0.25em"/>
                                  </mml:mrow>
                                </mml:mfrac>
                                <mml:mo>×</mml:mo>
                                <mml:mn>100</mml:mn>
                                <mml:mo>%</mml:mo>
                              </mml:math>
                            </p>
                          </td>
                        </tr>
                        <tr>
                          <td colspan="2" align="left" valign="top" rowspan="1">Secondary outcomes</td>
                        </tr>
                        <tr>
                          <td colspan="2" style="padding-left:10%" align="left" valign="top" rowspan="1">Food intake and appetite</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">3‐day food diary</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Participants were asked to complete a food diary for three consecutive days (one weekend day and two weekdays) in the week preceding Day 1 and again prior to Day 7 (completed during the week of study drug administration). The diary consists of three main mealtime points (breakfast, lunch and dinner) and three between‐meal snacks (mid‐morning, mid‐afternoon and evening). This method has been validated and has shown to reflect current dietary intake in this patient population. Total calories and relative macronutrients (fat, carbohydrates and protein) were analysed using FoodWorks (Version 7.01; Nutrition Company, Long Valley, NJ, USA).</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Test meal</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">A free‐choice test meal was administered at the screening/baseline visit and again 1 h following drug administration on Day 7. Participants were provided with a selection of previously identified preferred food items and instructed to eat as much as they wanted. Food items were weighed before and after each meal; the same food items and amounts were provided at each meal. Total caloric intake was analysed using FoodWorks (Version 7.01; Nutrition Company, Long Valley, NJ, USA).</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">VAS (mm)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">The VAS was administered while fasting and 1 h after the test meal at screening/baseline and Day 7. This a one‐item measure that quantifies subjective rating with a 100‐mm line anchored at 0 mm with the words ‘Not at all’ and at 100 mm with the word ‘Extremely’ where the participant makes a mark on the line indicative of their current hunger level.</td>
                        </tr>
                        <tr>
                          <td colspan="2" style="padding-left:10%" align="left" valign="top" rowspan="1">Functional performance</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">HGS (kg)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">HGS was assessed on Days 1 and 7 using a hand‐held dynamometer (Jamar Hydraulic Dynamometer, J.A. Preston Corp., Clifton, NJ, USA). Participants were asked to squeeze the dynamometer as hard as possible for 4 s. Three trials were performed on each hand with 30 s of rest in‐between; maximum HGS from each hand was averaged and used for analysis.</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">SCP (W)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">
                            <p>SCP was assessed on Days 1 and 7. Participants were asked to climb a standard flight of hospital stairs (13 steps, 15.3 cm each) as quickly as possible, using the handrail if necessary. Two to three trials were attempted with 1 min of rest in‐between. The shortest completion time was transformed into power and used for analysis where</p>
                            <p>
                              <mml:math id="jats-math-3" display="inline" overflow="scroll">
                                <mml:mi>W</mml:mi>
                                <mml:mo>=</mml:mo>
                                <mml:mfrac>
                                  <mml:mrow>
                                    <mml:mtext mathvariant="italic">body mass</mml:mtext>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mfenced open="(" close=")">
                                      <mml:mi mathvariant="italic">kg</mml:mi>
                                    </mml:mfenced>
                                    <mml:mo>×</mml:mo>
                                    <mml:mtext mathvariant="italic">acceleration of gravity</mml:mtext>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mfenced open="(" close=")">
                                      <mml:mrow>
                                        <mml:mn>9.81</mml:mn>
                                        <mml:mi>m</mml:mi>
                                        <mml:mo>/</mml:mo>
                                        <mml:msup>
                                          <mml:mi>s</mml:mi>
                                          <mml:mn>2</mml:mn>
                                        </mml:msup>
                                      </mml:mrow>
                                    </mml:mfenced>
                                    <mml:mo>×</mml:mo>
                                    <mml:mtext mathvariant="italic">vertical distance</mml:mtext>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mfenced open="(" close=")">
                                      <mml:mrow>
                                        <mml:mn>1.99</mml:mn>
                                        <mml:mspace width="0.25em"/>
                                        <mml:mi>m</mml:mi>
                                      </mml:mrow>
                                    </mml:mfenced>
                                  </mml:mrow>
                                  <mml:mrow>
                                    <mml:mtext mathvariant="italic">time</mml:mtext>
                                    <mml:mspace width="0.25em"/>
                                    <mml:mfenced open="(" close=")">
                                      <mml:mtext mathvariant="italic">seconds</mml:mtext>
                                    </mml:mfenced>
                                  </mml:mrow>
                                </mml:mfrac>
                              </mml:math>
                            </p>
                          </td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">KPS</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">The KPS was assessed on Days 1 and 7 by objective rating of physical function using 11 levels from 0% (dead) to 100% (normal functioning).</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">ECOG</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">The ECOG was assessed on Days 1 and 7 by objective rating of physical function using a simplified version of the KPS assessing five levels of functioning from 0 (<italic toggle="yes">normal functioning</italic>) to 5 (<italic toggle="yes">dead</italic>).</td>
                        </tr>
                        <tr>
                          <td colspan="2" style="padding-left:10%" align="left" valign="top" rowspan="1">Energy expenditure</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Indirect calorimetry</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Resting energy expenditure (REE) and respiratory quotient (RQ) were measured while fasting prior to drug administration on Days 1 and 7 via indirect calorimetry. Participants rested in a supine position for at least 30 min and then a transparent hood connected to an indirect calorimeter was placed over their head. Carbon dioxide (CO<sub>2</sub>) and oxygen (O<sub>2</sub>) content were measured for 30 min, with the average of the last 20 min used for analysis (Vmax Encore, Vyaire Medical, Inc., Mettawa, IL, USA). Percentage of predicted REE is expressed as the ratio of absolute REE/predicted REE (predicted REE was calculated by the Vyaire system using the Harris–Benedict equation), and RQ is expressed as the ratio of volume of CO<sub>2</sub> produced/volume of O<sub>2</sub> utilized (VCO<sub>2</sub>/VO<sub>2</sub>).</td>
                        </tr>
                        <tr>
                          <td colspan="2" style="padding-left:10%" align="left" valign="top" rowspan="1">Laboratory assays</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pharmacodynamics</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Plasma GH was measured while fasting prior to drug administration and again one‐hour after drug administration on Days 1 and 7, using the immunochemiluminometric assay ISD‐iSYS Human GH (Immunodiagnostics Systems Ltd.; LabCorp).</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">IGFBP‐3 (μg/mL)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Plasma IGFBP‐3 was measured while fasting prior to drug administration on Days 1 and 7 using the immunochemiluminometric assay ISD‐iSYS Human IGFBP‐3 (Immunodiagnostics Systems Ltd.; LabCorp).</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Glucose (mg/dL)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Plasma glucose was measured while fasting prior to drug administration on Days 1 and 7 through standard laboratory protocol at the Michael E. DeBakey VA Medical Center.</td>
                        </tr>
                        <tr>
                          <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">hs‐CRP (mg/L)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Plasma hs‐CRP was measured while fasting prior to drug administration on Days 1 and 7 through standard laboratory protocol at the Michael E. DeBakey VA Medical Center.</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot id="jcsm13191-ntgp-0002">
                      <fn id="jcsm13191-note-0002">
                        <p>Table <xref rid="jcsm13191-tbl-0001" ref-type="table">1</xref> shows the detailed description of study outcomes including outcome categorization and assessment methods.</p>
                      </fn>
                      <fn id="jcsm13191-note-0003">
                        <p>Abbreviations: ASAS, Anderson Symptom Assessment Scales; CO<sub>2</sub>, carbon dioxide; ECOG, Eastern Oncology Cooperative Group Scale of Performance Status; FACIT‐ F, Functional Assessment of Chronic Illness Therapy‐Fatigue; GH, growth hormone; HGS, hand grip strength; hs‐CRP, high‐sensitivity c‐reactive protein; IGF‐1, insulin‐like growth factor‐1; IGFBP‐3, insulin‐like growth factor binding protein‐3; KPS, Karnofsky Performance Scale; O<sub>2</sub>, oxygen; QOL, quality of life; REE, resting energy expenditure; RQ, respiratory quotient; SCP, stair climb power; SDS, standard deviation score; VAS, Visual Analogue Scale for Appetite.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="jcsm13191-sec-0011">
                  <title>Secondary outcomes</title>
                  <p><italic toggle="yes">Food intake:</italic> 3‐day food diary<xref rid="jcsm13191-bib-0033" ref-type="bibr"><sup>33</sup></xref> and free‐choice test meal. <italic toggle="yes">Appetite/hunger:</italic> Visual Analogue Scale (VAS) assessed while fasting before and 1‐h post‐meal. <italic toggle="yes">Functional performance:</italic> handgrip strength (HGS), stair climbing power (SCP), ECOG and Karnofsky Performance Scale (KPS). <italic toggle="yes">Indirect calorimetry:</italic> absolute REE (kcals/day), %predicted REE (absolute REE/predicted REE) and respiratory quotient (RQ). <italic toggle="yes">Fasting blood sample:</italic> pre‐dose for plasma GH, IGFBP‐3, glucose and hs‐CRP; change was Day 7 − Day 1. Another sample was taken 1‐h post‐dose for <italic toggle="yes">pharmacodynamics</italic> via plasma GH (post‐dose − pre‐dose).</p>
                </sec>
              </sec>
              <sec id="jcsm13191-sec-0012">
                <title>Statistics</title>
                <p>Because this is the first study that exposed subjects to more than a single dose of macimorelin, no data was available to perform a power analysis. Hence, this pilot, exploratory study was designed to assess safety and efficacy with the intent to generate data to power a future, larger clinical trial. An intent‐to‐treat non‐parametric analysis was conducted (SPSSv18, Inc., Chicago, IL, USA); data are presented as median (SEM) or <italic toggle="yes">N</italic> (%); statistical significance was two sided with <italic toggle="yes">α</italic> ≤ 0.05. Between‐ and within‐group comparisons were assessed via Mann–Whitney <italic toggle="yes">U</italic> test or Fisher's exact test. Associations between QOL change and other outcome changes were assessed via Spearman correlations.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jcsm13191-sec-0013">
              <title>Results</title>
              <sec id="jcsm13191-sec-0014">
                <title>Participants</title>
                <p>Of 9,129 patients screened for eligibility, 15 were eligible (<italic toggle="yes">Figure</italic> <xref rid="jcsm13191-fig-0002" ref-type="fig"><italic toggle="yes">2</italic></xref>), with the use of exclusionary medications (corticosteroids, highly emetogenic chemotherapy, drugs that prolong the QT interval) and exclusionary ALT/AST and creatinine lab values as the highest exclusionary factors (<italic toggle="yes">n</italic> = 706). In Phase 1, subjects were randomized to Group 1: 0.5 mg/kg macimorelin (<italic toggle="yes">N</italic> = 8) or placebo (<italic toggle="yes">N</italic> = 5). One patient from each arm discontinued before receiving all doses. Patients achieving the <italic toggle="yes">a priori</italic> efficacy criteria were: ≥0.8 kg body weight gain (macimorelin <italic toggle="yes">N</italic> = 2; placebo <italic toggle="yes">N</italic> = 0); ≥50 ng/mL IGF‐1 increase (macimorelin <italic toggle="yes">N</italic> = 0; placebo <italic toggle="yes">N</italic> = 0); or ≥15% QOL improvement from ASAS (macimorelin <italic toggle="yes">N</italic> = 2; placebo <italic toggle="yes">N</italic> = 1) or FACIT‐F (macimorelin <italic toggle="yes">N</italic> = 3; placebo <italic toggle="yes">N</italic> = 0). No adverse events were reported. The Data Review Committee conducted an interim analysis and determined that 0.5 mg/kg was safe with inadequate efficacy, and enrolment for Phase 2 began with Group 2 (1.0 mg/kg). New patients were randomized to macimorelin (<italic toggle="yes">N</italic> = 2) or placebo (<italic toggle="yes">N</italic> = 0) before the trial was closed due to poor accrual and study relocation. Participants receiving at least one of either macimorelin dose were combined (<italic toggle="yes">N</italic> = 10) for comparison to placebo (<italic toggle="yes">N</italic> = 5) due to the small sample size.</p>
                <fig position="float" fig-type="Figure" id="jcsm13191-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <p>CONSORT diagram. Flowchart of participants from pre‐screening through enrolment, randomization, follow‐up assessment and analysis. ECOG, Eastern Oncology Cooperative Group. *Allocation to Group 2 was initiated after Group 1 data collection was completed, and it was determined that 0.5 mg/kg was safe, but not efficacious. <sup>a</sup>Patient received one dose and did not complete Day 7 visit but did complete safety data for the post‐study visit. <sup>b</sup>Patient received two doses and completed body weight and safety assessments at the Day 7 and post‐study visits. <sup>c</sup>Includes discontinued patient.</p>
                  </caption>
                  <graphic xlink:href="JCSM-14-835-g004" position="anchor" id="jats-graphic-3"/>
                </fig>
                <sec id="jcsm13191-sec-0015">
                  <title>Primary outcomes</title>
                  <sec id="jcsm13191-sec-0016">
                    <title>Efficacy</title>
                    <p>Descriptive Characteristics at Day 1 were not different between groups (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0002" ref-type="table"><italic toggle="yes">2</italic></xref>); however, there was a trend for lower body weight and higher IGF‐1 in placebo than macimorelin. Proportion of patients achieving the <italic toggle="yes">a priori</italic> efficacy criteria was not different between groups; neither were changes (Day 7 − Day 1) in body weight, IGF‐1, ASAS or FACIT‐F (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0003" ref-type="table"><italic toggle="yes">3</italic></xref>). Macimorelin recipients scored better on ASAS pain (<italic toggle="yes">P</italic> = 0.05) and fatigue (<italic toggle="yes">P</italic> = 0.05) subscales at Day 7 (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0004" ref-type="table"><italic toggle="yes">4</italic></xref>).</p>
                    <table-wrap position="float" id="jcsm13191-tbl-0002" content-type="Table">
                      <label>Table 2</label>
                      <caption>
                        <p>Descriptive characteristics assessed pre‐dose at Day 1</p>
                      </caption>
                      <table frame="hsides" rules="groups">
                        <col align="left" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="." span="1"/>
                        <thead valign="bottom">
                          <tr style="border-bottom:solid 1px #000000">
                            <th align="left" valign="bottom" rowspan="1" colspan="1">Median (SEM) or <italic toggle="no">N</italic> (%)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Placebo (<italic toggle="no">N</italic> = 5)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Macimorelin (<italic toggle="no">N</italic> = 10)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1"><italic toggle="no">P</italic> value<xref rid="jcsm13191-note-0006" ref-type="table-fn"><sup>a</sup></xref>
</th>
                          </tr>
                        </thead>
                        <tbody valign="top">
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">68.0 (2.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">65.5 (2.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.70</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Height (cm)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">167.6 (3.6)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">172.1 (2.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.98</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">53.5 (3.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">67.9 (3.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.08</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">18.7 (1.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">23.1 (1.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.17</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">6‐month weight change (%)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−10.3 (1.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−14.3 (1.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.21</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">12‐month weight change (%)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−10.3 (4.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−18.9 (3.6)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.17</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">IGF‐1 (ng/mL)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">113.0 (35.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">79.0 (13.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.09</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">IGF‐1 (SDS)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.9 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.06</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">ASAS Abs. score</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">74.0 (11.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">81.0 (3.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">FACIT‐F Adj. score</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">63.8 (4.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">69.9 (5.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.54</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Male</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">4 (80.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10 (100.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Ethnicity</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White, non‐Hispanic</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3 (60.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6 (60.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White, Hispanic</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3 (30.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Black</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (10.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Tumour system</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.88</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2 (40.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">5 (50.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Respiratory</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2 (40.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3 (30.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Genitourinary</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hematologic</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (10.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Neuroendocrine</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (10.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Stage</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">II</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2 (20.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">III</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (10.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IV</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">4 (80.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6 (60.0)</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (10.0)<xref rid="jcsm13191-note-0007" ref-type="table-fn"><sup>b</sup></xref>
</td>
                            <td align="left" valign="top" rowspan="1" colspan="1"/>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Recent chemotherapy<xref rid="jcsm13191-note-0008" ref-type="table-fn"><sup>c</sup></xref>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7 (70.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.12</td>
                          </tr>
                          <tr>
                            <td align="left" valign="top" rowspan="1" colspan="1">Recent radiation<xref rid="jcsm13191-note-0008" ref-type="table-fn"><sup>c</sup></xref>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2 (20.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                          </tr>
                        </tbody>
                      </table>
                      <table-wrap-foot id="jcsm13191-ntgp-0003">
                        <fn id="jcsm13191-note-0004">
                          <p><italic toggle="yes">Note</italic>: Table <xref rid="jcsm13191-tbl-0002" ref-type="table">2</xref> shows the descriptive characteristics assessed at Day 1 for patients receiving at least one dose of placebo or macimorelin.</p>
                        </fn>
                        <fn id="jcsm13191-note-0005">
                          <p>Abbreviations: Abs, absolute; Adj, adjusted; ASAS, Anderson Symptom Assessment Score; BMI, body mass index; FACIT‐F, Functional Assessment of Chronic Illness Therapy‐Fatigue; IGF, insulin‐like growth factor; SDS, standard deviation score.</p>
                        </fn>
                        <fn id="jcsm13191-note-0006">
                          <label>
                            <sup>a</sup>
                          </label>
                          <p>Significance calculated via Mann–Whitney <italic toggle="yes">U</italic> test for continuous variables and Fisher's exact test for categorical variables.</p>
                        </fn>
                        <fn id="jcsm13191-note-0007">
                          <label>
                            <sup>b</sup>
                          </label>
                          <p>Diagnosis of multiple myeloma.</p>
                        </fn>
                        <fn id="jcsm13191-note-0008">
                          <label>
                            <sup>c</sup>
                          </label>
                          <p>Exposure within 3 months prior to screening/baseline visit.</p>
                        </fn>
                      </table-wrap-foot>
                    </table-wrap>
                    <table-wrap position="float" id="jcsm13191-tbl-0003" content-type="Table">
                      <label>Table 3</label>
                      <caption>
                        <p>Change scores for primary outcomes, test meal and energy expenditure</p>
                      </caption>
                      <table frame="hsides" rules="groups">
                        <col align="left" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="." span="1"/>
                        <thead valign="bottom">
                          <tr style="border-bottom:solid 1px #000000">
                            <th align="left" valign="bottom" rowspan="1" colspan="1">Change: median (SEM) or <italic toggle="no">N</italic> (%)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Placebo (<italic toggle="no">N</italic> = 4)<xref rid="jcsm13191-note-0011" ref-type="table-fn"><sup>a</sup></xref>
</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Macimorelin (<italic toggle="no">N</italic> = 9)<xref rid="jcsm13191-note-0012" ref-type="table-fn"><sup>b</sup></xref>
</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1"><italic toggle="no">P</italic> value<xref rid="jcsm13191-note-0013" ref-type="table-fn"><sup>c</sup></xref>
</th>
                          </tr>
                        </thead>
                        <tbody valign="top">
                          <tr>
                            <td colspan="4" align="left" valign="top" rowspan="1">Primary efficacy outcomes and efficacy criteria</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Body weight (kg)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.18 (0.21)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.27)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.64</td>
                          </tr>
                          <tr>
                            <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≥0.8 kg increase</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2 (22)<xref rid="jcsm13191-note-0014" ref-type="table-fn"><sup>d</sup></xref>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.92</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IGF‐1 (ng/mL)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">23.0 (3.93)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">9 (6.69)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.12</td>
                          </tr>
                          <tr>
                            <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≥50 ng/mL increase</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ASAS Abs. score</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6.7 (7.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">13.5 (5.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.89</td>
                          </tr>
                          <tr>
                            <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≥15% increase</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1 (25)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">4 (44)<xref rid="jcsm13191-note-0015" ref-type="table-fn"><sup>e</sup></xref>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">FACIT‐F Adj. score</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.2 (5.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.9 (4.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.76</td>
                          </tr>
                          <tr>
                            <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≥15% increase</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0 (0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3 (33)<xref rid="jcsm13191-note-0014" ref-type="table-fn"><sup>d</sup></xref>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                          </tr>
                          <tr>
                            <td colspan="4" align="left" valign="top" rowspan="1">Secondary outcomes</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Scr: appetite change (mm)<sup>f</sup>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−35.5 (9.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−1.0 (14.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.54</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Day 7: appetite change (mm) <sup>f</sup>
</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (11.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−47.5 (17.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.40</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Test meal caloric intake (kcals)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−78 (130)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">59 (123)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.22</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Absolute REE (kcals)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">34 (49)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">49 (51)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">% Predicted REE</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3.0 (4.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">4.0 (3.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.94</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">RQ</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.01 (0.01)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.01 (0.02)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.88</td>
                          </tr>
                        </tbody>
                      </table>
                      <table-wrap-foot id="jcsm13191-ntgp-0004">
                        <fn id="jcsm13191-note-0009">
                          <p><italic toggle="yes">Note</italic>: Table <xref rid="jcsm13191-tbl-0003" ref-type="table">3</xref> shows change scores (Day 7 − Day 1 unless otherwise noted) for primary efficacy outcomes, appetite/test meal and exergy expenditure in patients receiving all seven doses of placebo or macimorelin and completing Days 1 and 7 visits; also displaying proportion of subjects in each study arm achieving the <italic toggle="yes">a priori</italic> determined primary efficacy criteria.</p>
                        </fn>
                        <fn id="jcsm13191-note-0010">
                          <p><italic toggle="yes">Note</italic>: Abs, absolute; Adj, adjusted; Scr, Screening/Baseline Visit; ASAS, Anderson Symptom Assessment Score; FACIT‐F, Functional Assessment of Chronic Illness Therapy‐Fatigue; IGF, insulin‐like growth factor; REE, resting energy expenditure; RQ, respiratory quotient.</p>
                        </fn>
                        <fn id="jcsm13191-note-0011">
                          <label>
                            <sup>a</sup>
                          </label>
                          <p>One subject only received one dose and did not complete Day 7 visit.</p>
                        </fn>
                        <fn id="jcsm13191-note-0012">
                          <label>
                            <sup>b</sup>
                          </label>
                          <p>One subject only received two doses and completed body weight and safety assessments at the Day 7 visit but is only included in safety analysis, not efficacy.</p>
                        </fn>
                        <fn id="jcsm13191-note-0013">
                          <label>
                            <sup>c</sup>
                          </label>
                          <p>Significance calculated via Mann–Whitney <italic toggle="yes">U</italic> test for continuous variables and Fisher's exact test for categorical variables.</p>
                        </fn>
                        <fn id="jcsm13191-note-0014">
                          <label>
                            <sup>d</sup>
                          </label>
                          <p>All from 0.5 mg/kg.</p>
                        </fn>
                        <fn id="jcsm13191-note-0015">
                          <label>
                            <sup>e</sup>
                          </label>
                          <p>Two from 0.5 mg/kg and two from 1.0 mg/kg.</p>
                        </fn>
                      </table-wrap-foot>
                    </table-wrap>
                    <table-wrap position="float" id="jcsm13191-tbl-0004" content-type="Table">
                      <label>Table 4</label>
                      <caption>
                        <p>Day 1 and change scores at Day 7 for physical function, food recall, QOL and laboratory parameters</p>
                      </caption>
                      <table frame="hsides" rules="groups">
                        <col align="left" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="(" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <thead valign="bottom">
                          <tr style="border-bottom:solid 1px #000000">
                            <th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Median (SEM)</th>
                            <th colspan="3" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">Placebo</th>
                            <th colspan="3" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">Macimorelin</th>
                            <th rowspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" colspan="1"><italic toggle="no">P</italic> value Day 1<xref rid="jcsm13191-note-0018" ref-type="table-fn"><sup>a</sup></xref>
</th>
                            <th rowspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" colspan="1"><italic toggle="no">P</italic> value Day 7<xref rid="jcsm13191-note-0018" ref-type="table-fn"><sup>a</sup></xref>
</th>
                            <th rowspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" colspan="1"><italic toggle="no">P</italic> value change<xref rid="jcsm13191-note-0018" ref-type="table-fn"><sup>a</sup></xref>
</th>
                          </tr>
                          <tr style="border-bottom:solid 1px #000000">
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Day 1 (<italic toggle="no">N</italic> = 5)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Day 7 (<italic toggle="no">N</italic> = 4)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Change (<italic toggle="no">N</italic> = 4)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Day 1 (<italic toggle="no">N</italic> = 10)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Day 7 (<italic toggle="no">N</italic> = 9)</th>
                            <th align="center" valign="bottom" rowspan="1" colspan="1">Change (<italic toggle="no">N</italic> = 9)</th>
                          </tr>
                        </thead>
                        <tbody valign="top">
                          <tr>
                            <td colspan="10" align="left" valign="top" rowspan="1">Functional performance</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HGS (kg)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">26.7 (2.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">28.1 (2.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.40 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">30.0 (1.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">28.7 (1.6)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.3 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.37</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.81</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SCP (W)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">144.6 (16.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">137.6 (11.6)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−5.9 (5.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">124.0 (19.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">136.4 (13.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−5.1 (8.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.68</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ECOG (rating)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.24)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.51</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.15</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">KPS (rating)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">100.0 (2.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">100.0 (2.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">95.0 (2.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">90.0 (2.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.68</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.84</td>
                          </tr>
                          <tr>
                            <td colspan="10" align="left" valign="top" rowspan="1">3‐Day Food Diary</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Calories/day (kcal)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2,117 (475)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1,936 (427)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">96 (343)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1,629 (193)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1,325 (297)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−211 (243)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.77</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.94</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">% Fat/day</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">32.0 (3.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">36.0 (3.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (2.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">36.0 (3.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">30.0 (2.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−2.0 (3.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.30</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.20</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.039</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">% Protein/day</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">16.5 (1.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">16.5 (2.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">16.0 (4.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">15.0 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.00</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.99</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">% Carbohydrate/day</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">52.0 (5.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">47.0 (6.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−6.5 (2.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">41.5 (3.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">45.0 (6.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−1.0 (4.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.04</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.60</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.27</td>
                          </tr>
                          <tr>
                            <td colspan="10" align="left" valign="top" rowspan="1">ASAS</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pain</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">5.0 (1.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.5 (1.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">9.0 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.10</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.05</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">5.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6.5 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">9.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.10</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.05</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.94</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (1.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.51</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Depression</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">9.0 (1.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.31</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Anxiety</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">9.0 (1.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.44</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.94</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Drowsiness</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (1.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">9.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.17</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.41</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.94</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Shortness of breath</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (1.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">10.0 (0.6)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.44</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.60</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Appetite</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6.0 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7.5 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.5 (1.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">5.5 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.77</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.60</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sleep</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7.0 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6.5 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−1.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">6.0 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.44</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.60</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.33</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Well‐being</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7.0 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7.5 (1.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">7.5 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">8.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.68</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.94</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                          </tr>
                          <tr>
                            <td colspan="10" align="left" valign="top" rowspan="1">FACIT‐F</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Physical well‐being</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">17.0 (1.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">17.0 (2.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">21.5 (2.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">24.0 (1.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.51</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.26</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.15</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Social/Family well‐being</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">19.0 (1.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">18.0 (1.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−1.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">19 (2.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">18.0 (2.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.0 (1.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.86</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.83</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.60</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Emotional well‐being</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">16.0 (1.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">17.0 (2.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.5 (2.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">18.0 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">19.0 (0.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.77</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Functional well‐being</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">17.0 (1.8)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">17.0 (1.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.5 (1.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">14.5 (2.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">17.0 (3.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (2.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.86</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">33.0 (2.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">31.5 (4.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3.0 (3.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">38.5 (2.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">41.0 (2.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−1.0 (3.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.51</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.41</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.60</td>
                          </tr>
                          <tr>
                            <td colspan="10" align="left" valign="top" rowspan="1">Laboratory assays</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IGFBP‐3 (μg/mL)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3.1 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">3.45 (0.86)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.10 (0.2)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2.5 (0.3)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">2.7 (0.35)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.25 (0.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.19</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.11</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.93</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Glucose (mg/dL)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">105.0 (5.1)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">105.5 (11.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−3.5 (9.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">95.0 (19.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">101.0 (5.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.0 (23.0)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.44</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.50</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.71</td>
                          </tr>
                          <tr>
                            <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">hs‐CRP (mg/L)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.4 (0.6)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.1 (0.9)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.4 (0.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">1.5 (0.5)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.4 (0.7)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">−0.5 (0.4)</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.85</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.57</td>
                            <td align="char" valign="top" rowspan="1" colspan="1">0.93</td>
                          </tr>
                        </tbody>
                      </table>
                      <table-wrap-foot id="jcsm13191-ntgp-0005">
                        <fn id="jcsm13191-note-0016">
                          <p><italic toggle="yes">Note</italic>: Table <xref rid="jcsm13191-tbl-0004" ref-type="table">4</xref> shows Day 1 values and change scores at Day 7 (Day 7 − Day 1) for secondary outcomes including physical function, food recall and patient‐reported quality of life outcomes.</p>
                        </fn>
                        <fn id="jcsm13191-note-0017">
                          <p>Abbreviations: ASAS, Anderson Symptom Assessment Score; ECOG, Eastern Oncology Cooperative Group; FACIT‐Fatigue, Functional Assessment of Chronic Illness Treatment‐Fatigue; HGS, handgrip strength; hs‐CRP, highly sensitive C‐reactive protein; IGFBP, insulin‐like growth factor binding‐protein; KPS, Karnofsky Performance Scale; QOL, quality of life; SCP, stair climb power.</p>
                        </fn>
                        <fn id="jcsm13191-note-0018">
                          <label>
                            <sup>a</sup>
                          </label>
                          <p>Significance calculated via Mann–Whitney <italic toggle="yes">U</italic> test.</p>
                        </fn>
                      </table-wrap-foot>
                    </table-wrap>
                  </sec>
                  <sec id="jcsm13191-sec-0017">
                    <title>Safety</title>
                    <p>One patient in placebo discontinued the study after one dose due to initiation of an exclusionary medication (QT‐prolonging chemotherapy); one patient in macimorelin (0.5 mg/kg) discontinued the study after receiving two doses due to non‐compliance. No related serious or non‐serious adverse events were reported, including no abnormal laboratory or ECG parameters. One unrelated serious adverse event occurred in one patient who received 0.5 mg/kg macimorelin and reported hospitalization with infection treatment for forearm soft tissue necrosis at the post‐study visit; this patient had initiated radiation treatment 3 days after Day 7, and the oncology providers determined that it was a radiation‐related infection. Non‐serious, unrelated events included (1) one patient who received 1.0‐mg/kg macimorelin reported abdominal pain, nausea and herpes breakout at Day 7 (all symptoms were recurrent); (2) one patient who received 1.0 mg/kg macimorelin reported pedal oedema at the post‐study visit (determined a likely chemotherapy effect).</p>
                  </sec>
                </sec>
                <sec id="jcsm13191-sec-0018">
                  <title>Secondary outcomes</title>
                  <sec id="jcsm13191-sec-0019">
                    <title>Food intake, appetite, energy expenditure and functional performance</title>
                    <p>Fasted hunger rating (macimorelin: 45.5 [9.7] vs. placebo: 48.0 [3.7] mm; <italic toggle="yes">P</italic> = 1.00) and test meal caloric intake (macimorelin: 1094 [122] vs. placebo: 1082 [188] kcals; <italic toggle="yes">P</italic> = 0.62) were not different between groups at the screening/baseline visit. Neither was the change (Day 7 − Day 1) in fasted hunger rating (macimorelin: 7.0 [11.3] vs. placebo: −27.5 [23.6] mm; <italic toggle="yes">P</italic> = 0.54). Test meal‐induced change (post‐meal − fasted) in hunger rating was not different between groups at screening/baseline or Day 7 (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0003" ref-type="table"><italic toggle="yes">3</italic></xref>). Change in test meal caloric intake was not different between‐groups (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0003" ref-type="table"><italic toggle="yes">3</italic></xref>), but caloric intake was greater in macimorelin on Day 7 (macimorelin: 1110.0 [141.2] vs. placebo: 509.0 [311.9], <italic toggle="yes">P</italic> = 0.03). At Day 1, absolute REE (macimorelin: 1432 [109] vs. placebo: 1400 [67] kcals/day; <italic toggle="yes">P</italic> = 0.86), percentage of predicted REE (macimorelin: 112.0 [7.3] vs. placebo: 101.0 [6.7] %; <italic toggle="yes">P</italic> = 0.94) and RQ (macimorelin: 0.81 [0.0] vs. placebo: 0.82 [0.0] VCO<sub>2</sub>/VO<sub>2</sub>; <italic toggle="yes">P</italic> = 1.00) were not different between groups; neither were change scores (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0003" ref-type="table"><italic toggle="yes">3</italic></xref>). Neither Day 1 nor change in HGS, SCP, ECOG KPS or average daily caloric intake from the 3‐day food diary were different between groups (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0004" ref-type="table"><italic toggle="yes">4</italic></xref>).</p>
                  </sec>
                  <sec id="jcsm13191-sec-0020">
                    <title>Laboratory assays</title>
                    <p>There was no difference between groups in pre‐dose (fasting) GH (macimorelin: 2.2 [0.6] vs. placebo: 2.1 [1.1] ng/mL; <italic toggle="yes">P</italic> = 0.78), IGFBP‐3, glucose, or hs‐CRP Day 1 (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0004" ref-type="table"><italic toggle="yes">4</italic></xref>). Neither was change at Day 7 in pre‐dose GH (macimorelin: 0.70 [1.17] vs. placebo: −0.50 [0.99] ng/mL; <italic toggle="yes">P</italic> = 0.20), IGFBP‐3, glucose, or hs‐CRP (<italic toggle="yes">Table</italic> <xref rid="jcsm13191-tbl-0004" ref-type="table"><italic toggle="yes">4</italic></xref>). One‐hour post‐dose GH was elevated compared with fasting GH for macimorelin group but not placebo at Days 1 and 7 (<italic toggle="yes">Figure</italic>
<xref rid="jcsm13191-fig-0003" ref-type="fig"><italic toggle="yes">3</italic><italic toggle="yes">A,B</italic></xref>). The within‐group GH difference (post‐dose − fasting) was not different between Days 1 and 7 for macimorelin (Day 1: 18.5 [2.8] vs. Day 7: 8.8 [2.7] ng/mL; <italic toggle="yes">P</italic> = 0.21) or placebo (Day 1: 0.7 [1.0] vs. Day 7: 0.3 [0.5] ng/mL; <italic toggle="yes">P</italic> = 0.35).</p>
                    <fig position="float" fig-type="Figure" id="jcsm13191-fig-0003">
                      <label>Figure 3</label>
                      <caption>
                        <p>(<italic toggle="no">A,B</italic>) study drug pharmacodynamics measured by GH. Line graphs for growth hormone (GH) levels assessed prior to (fasting) and 1‐h post drug administration on Day 1 (<italic toggle="no">A</italic>: placebo, <italic toggle="no">N</italic> = 4; macimorelin, <italic toggle="no">N</italic> = 10) and Day 7 (<italic toggle="no">B</italic>: placebo, <italic toggle="no">N</italic> = 3; macimorelin, <italic toggle="no">N</italic> = 9). *fasting versus post‐dose, <italic toggle="no">P</italic> ≤ 0.01.</p>
                      </caption>
                      <graphic xlink:href="JCSM-14-835-g001" position="anchor" id="jats-graphic-5"/>
                    </fig>
                  </sec>
                  <sec id="jcsm13191-sec-0021">
                    <title>Correlations between QOL and other outcome measures</title>
                    <p>In macimorelin recipients, percentage of change in ASAS total score was indirectly correlated with change in daily relative protein intake (<italic toggle="yes">r</italic> = −0.686; <italic toggle="yes">P</italic> = 0.04). Relative change in FACIT‐F adjusted score was directly correlated with change in body weight, IGF‐1 and test meal caloric intake and indirectly correlated with change in absolute REE (<italic toggle="yes">Figure</italic>
<xref rid="jcsm13191-fig-0004" ref-type="fig"><italic toggle="yes">4</italic><italic toggle="yes">A–D</italic></xref>).</p>
                    <fig position="float" fig-type="Figure" id="jcsm13191-fig-0004">
                      <label>Figure 4</label>
                      <caption>
                        <p>(<italic toggle="no">A–E</italic>) correlations between quality of life change and study outcome change in Macimorelin recipients. Scatterplots of Spearman correlations between relative change (Day 7 − Day 1) in FACIT‐F adjusted score and absolute change (Day 7 − Day 1) in body weight (<italic toggle="no">A</italic>), IGF‐1 (<italic toggle="no">B</italic>), test meal total caloric intake (<italic toggle="no">C</italic>) and REE (<italic toggle="no">D</italic>) for participants receiving all seven doses of macimorelin; <italic toggle="no">N</italic> = 9 for all panels. FACIT‐F, Functional Assessment of Chronic Illness Therapy‐Fatigue; IGF, insulin‐like growth factor; REE, resting energy expenditure.</p>
                      </caption>
                      <graphic xlink:href="JCSM-14-835-g003" position="anchor" id="jats-graphic-7"/>
                    </fig>
                  </sec>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jcsm13191-sec-0022">
              <title>Discussion</title>
              <p>Cachexia is a common cancer sequela associated with poor prognosis and development of new treatment options is greatly needed. The ghrelin/GHSR‐1a pathway is the most advanced pathway being targeted for this indication, although no approved drug is currently available in most countries. This pilot study is the first to test efficacy and safety of the novel ghrelin mimetic, macimorelin, as a cancer cachexia treatment and the first multi‐dose study of this drug. Macimorelin was well‐tolerated with no related serious or non‐serious adverse events, including no abnormal laboratory or ECG parameters. While no significant improvements in efficacy were observed after 1 week of daily macimorelin compared with placebo, the proportion of patients achieving the <italic toggle="yes">a priori</italic> efficacy criteria for change in body weight and QOL were numerically higher in macimorelin, and QOL improvement was associated with improved body weight, IGF‐1 and caloric intake and with reduced energy expenditure in macimorelin recipients.</p>
              <p>The only approved treatment for cancer cachexia is anamorelin, another GHS, approved in Japan and undergoing Phase III trials elsewhere.<xref rid="jcsm13191-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jcsm13191-bib-0017" ref-type="bibr"><sup>17</sup></xref> Macimorelin was recently approved by the FDA and EMA for AGHD diagnosis,<xref rid="jcsm13191-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jcsm13191-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="jcsm13191-bib-0029" ref-type="bibr"><sup>29</sup></xref> which occurred after the current trial began. The most common adverse reactions reported in the related US prescribing information include dysgeusia (4.5%), dizziness, headache, fatigue (4% each), nausea, hunger (3% each), diarrhoea, upper respiratory tract infection (2% each), feeling hot, hyperhidrosis, nasopharyngitis and sinus bradycardia (1% each). In a thorough QT trial, macimorelin caused an increase of about 11 ms in the QTc interval. In our study, the use of QT‐prolonging drugs was exclusionary, and no adverse events, including QT‐prolongation, were reported with 7 days of administration.</p>
              <p>Cachexia‐related weight loss is adversely associated with cancer prognosis, QOL and physical function.<xref rid="jcsm13191-bib-0034" ref-type="bibr"><sup>34</sup></xref> While macimorelin did not significantly improve body weight in the current study, two of the nine macimorelin participants receiving all seven doses met the weight gain efficacy criterion, which was not met by any placebo patients. This criterion was based on a similar study where 3 days of daily anamorelin significantly increased body weight in cancer cachexia patients by 0.77 kg, while those on placebo lost 0.33 kg.<xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref> These differences could be due to variability in potency of doses used in these compounds or malabsorption due to gastrointestinal malignancy, although other factors like sex differences may have contributed. Longer duration anamorelin treatment increased lean mass in addition to body weight in patients with cancer cachexia.<xref rid="jcsm13191-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jcsm13191-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jcsm13191-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jcsm13191-bib-0018" ref-type="bibr"><sup>18</sup></xref> Like the current study, those studies did not report improved physical function. Future studies with higher doses and/or longer duration macimorelin may benefit from assessment of body composition and clinically relevant outcomes like fatigue, appetite and physical function, including potential sex differences.</p>
              <p>Cancer cachexia may promote ghrelin resistance, wherein elevated ghrelin is seen simultaneously with depressed appetite, which might be overcome by exogenous ghrelin/GHS administration.<xref rid="jcsm13191-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="jcsm13191-bib-0036" ref-type="bibr"><sup>36</sup></xref> Macimorelin did not impact appetite, food intake or energy expenditure in the current study, which could suggest ghrelin resistance, but more likely suggests an insufficient macimorelin dose because appetite stimulation is a known class effect of ghrelin/GHS.<xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jcsm13191-bib-0037" ref-type="bibr"><sup>37</sup></xref>, <xref rid="jcsm13191-bib-0038" ref-type="bibr"><sup>38</sup></xref> Cancer cachexia may also promote GH resistance wherein elevated GH is observed alongside low IGF‐1, which may be similarly overcome by exogenous ghrelin/GHS administration.<xref rid="jcsm13191-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="jcsm13191-bib-0036" ref-type="bibr"><sup>36</sup></xref> Anamorelin increased IGF‐1 by 54 ng/mL in cancer cachexia patients after 3 days of administration,<xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref> which was the basis for the IGF‐1 efficacy criterion in the current study. No macimorelin recipients achieved IGF‐1 efficacy here despite maintained GH secretion. In that study, GH response (30 min post–pre‐anamorelin) averaged over twice that observed here, likely due to the larger dose (~1.0 mg/kg)<xref rid="jcsm13191-bib-0014" ref-type="bibr"><sup>14</sup></xref>; however, macimorelin consistently induced acute GH secretion after single‐dose administration in non‐cancer individuals.<xref rid="jcsm13191-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jcsm13191-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jcsm13191-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="jcsm13191-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="jcsm13191-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="jcsm13191-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="jcsm13191-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="jcsm13191-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="jcsm13191-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="jcsm13191-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="jcsm13191-bib-0029" ref-type="bibr"><sup>29</sup></xref> Therefore, GH resistance is an unlikely contributor to the lack of efficacy observed here, evidenced by post‐macimorelin GH ≥ 5.1 ng/mL<xref rid="jcsm13191-bib-0039" ref-type="bibr"><sup>39</sup></xref> for all macimorelin recipients. One‐hour post‐macimorelin GH decreased approximately 50% (non‐significantly) after 1 week in the current study. The potential waning of GH stimulation could be from a compensatory somatostatin increase, which antagonizes GHS action on somatotrophs,<xref rid="jcsm13191-bib-0040" ref-type="bibr"><sup>40</sup></xref> but our observations imply that this potential negative feedback did not impede somatotropic axis activation.</p>
              <p>Longer duration GHS administration consistently improved patient‐reported QOL in cancer cachexia.<xref rid="jcsm13191-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jcsm13191-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jcsm13191-bib-0018" ref-type="bibr"><sup>18</sup></xref> The ROMANA1/2 trials reported anorexia/cachexia improvement after 12 weeks of daily anamorelin compared with placebo, which was detectable after 3 weeks, with a trend for stable fatigue with anamorelin and a worsening with placebo.<xref rid="jcsm13191-bib-0018" ref-type="bibr"><sup>18</sup></xref> Anorexia/cachexia improvement was only sustained for an additional 4 weeks of a 12‐week ROMANA1/2 extension trial (ROMANA3), implying that anamorelin efficacy may wane over time.<xref rid="jcsm13191-bib-0012" ref-type="bibr"><sup>12</sup></xref> In two subsequent trials, 12 weeks of anamorelin improved various patient‐reported parameters (activity, function, appetite, meal satisfaction and overall QOL) compared with placebo<xref rid="jcsm13191-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jcsm13191-bib-0017" ref-type="bibr"><sup>17</sup></xref>; fatigue was unaffected.<xref rid="jcsm13191-bib-0016" ref-type="bibr"><sup>16</sup></xref> A significant impact on QOL was undetected presently, but macimorelin recipients reported less pain and fatigue than placebo at Day 7. Additionally, two of the four macimorelin participants who met the QOL efficacy requirement received 1.0 mg/kg, suggesting that higher doses would have been more efficacious, although our final sample size was not powered to detect differences between doses. In macimorelin recipients, change in adjusted FACIT‐F total score displayed very strong, direct correlations with changes in body weight, IGF‐1 and test meal caloric intake and a strong, indirect correlation with change in REE. These findings are consistent with a meta‐analysis, which identified nutritional intake maximization as among the most propitious interventions for QOL improvement.<xref rid="jcsm13191-bib-0041" ref-type="bibr"><sup>41</sup></xref> While limited by sample size, these preliminary observations suggest a potential mechanism for macimorelin‐induced QOL improvement via increased body weight, IGF‐1 (as a marker of GH action), and nutritional intake and reduced metabolic demand.</p>
              <p>This is the first study to administer macimorelin in the cancer setting and first to administer repeated doses. This pilot clinical trial was designed with many strengths including double‐blinding, placebo controls, sequential doses and an array of clinically relevant outcomes. However, the small/uneven sample size, somewhat arbitrary efficacy criteria used to guide dose selection, trend for imbalanced Day 1 weight and combined doses limit interpretation of observations. We report that 1‐week daily macimorelin for cancer cachexia is safe and well‐tolerated. Efficacy of GHSR1a stimulation from this regimen was only sufficient for improving QOL and body weight in some individuals; however, these observations may provide preliminary evidence of macimorelin‐mediated QOL improvement through improved body weight, caloric intake and energy expenditure. This pilot study supports development of well‐powered, long‐term, dose‐escalation studies to examine efficacy of macimorelin on QOL, body composition, appetite/food intake, energy expenditure and physical function in cancer cachexia.</p>
            </sec>
            <sec id="jcsm13191-sec-0025">
              <title>Funding</title>
              <p>Macimorelin was provided by Aeterna Zentaris Inc. Work was funded by Puget Sound Veterans Affairs Health Care System and Michael E. DeBakey Veterans Affairs Medical Center. Jose Garcia receives research support from the Veterans Affairs (BX002807), the Congressionally Directed Medical Research Program (PC170059), and the National Institutes of Health (R01CA239208, R01AG061558 and R01AR067319). Lindsey Anderson receives research support from the University of Washington (DK007247) and the Veterans Affairs (RX03245). Ramiro Salas receives research support from the Veterans Affairs (I01CX001937).</p>
            </sec>
            <sec sec-type="COI-statement" id="jcsm13191-sec-0024">
              <title>Conflict of interest</title>
              <p>Megan Herodes declares that she has no conflict of interest. Lindsey Anderson declares that she has no conflict of interest. Samuel Shober declares that he has no conflict of interest. Ellen Schur declares that she has no conflict of interest. Solomon Graf declares that he has no conflict of interest. Nicola Ammer is an employee of Aeterna Zentaris GmbH. Marco Marcelli declares that he has no conflict of interest. Jose Garcia received research support from Aeterna Zentaris GmbH. and Novo Nordisk. Submitting authors have liaised with all co‐authors and confirm agreement with the final manuscript.</p>
              <p>The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the <italic toggle="yes">Journal of Cachexia, Sarcopenia and Muscle</italic>.<xref rid="jcsm13191-bib-0042" ref-type="bibr"><sup>42</sup></xref> This protocol was approved by the respective Institutional Review Boards and Research and Development Committees and was conducted in accordance with the Declaration of Helsinki and its amendments and the International Conference on Harmonization Guideline for Good Clinical Practices; all persons gave their informed consent prior to their inclusion in the study.</p>
            </sec>
          </body>
          <back>
            <ack id="jcsm13191-sec-0023">
              <title>Acknowledgements</title>
              <p>This project was supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases‐funded Nutrition Obesity Research Center (DK035816) and Diabetes Research Center (P30 DK017047) at the University of Washington.</p>
            </ack>
            <ref-list id="jcsm13191-bibl-0001" content-type="cited-references">
              <title>References</title>
              <ref id="jcsm13191-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0002"><string-name><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name><surname>Colombet</surname><given-names>M</given-names></string-name>, <string-name><surname>Soerjomataram</surname><given-names>I</given-names></string-name>, <string-name><surname>Parkin</surname><given-names>DM</given-names></string-name>, <string-name><surname>Pineros</surname><given-names>M</given-names></string-name>, <string-name><surname>Znaor</surname><given-names>A</given-names></string-name>, et al. <article-title>Cancer statistics for the year 2020: an overview</article-title>. <source>Int J Cancer</source><year>2021</year>;<volume>149</volume>:<fpage>778</fpage>–<lpage>789</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0003"><string-name><surname>Argiles</surname><given-names>JM</given-names></string-name>, <string-name><surname>Busquets</surname><given-names>S</given-names></string-name>, <string-name><surname>Stemmler</surname><given-names>B</given-names></string-name>, <string-name><surname>Lopez‐Soriano</surname><given-names>FJ</given-names></string-name>. <article-title>Cancer cachexia: understanding the molecular basis</article-title>. <source>Nat Rev Cancer</source><year>2014</year>;<volume>14</volume>:<fpage>754</fpage>–<lpage>762</lpage>.<pub-id pub-id-type="pmid">25291291</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0004"><string-name><surname>Teunissen</surname><given-names>SC</given-names></string-name>, <string-name><surname>Wesker</surname><given-names>W</given-names></string-name>, <string-name><surname>Kruitwagen</surname><given-names>C</given-names></string-name>, <string-name><surname>de Haes</surname><given-names>HC</given-names></string-name>, <string-name><surname>Voest</surname><given-names>EE</given-names></string-name>, <string-name><surname>de Graeff</surname><given-names>A</given-names></string-name>. <article-title>Symptom prevalence in patients with incurable cancer: a systematic review</article-title>. <source>J Pain Symptom Manage</source><year>2007</year>;<volume>34</volume>:<fpage>94</fpage>–<lpage>104</lpage>.<pub-id pub-id-type="pmid">17509812</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0005"><string-name><surname>Fearon</surname><given-names>K</given-names></string-name>, <string-name><surname>Strasser</surname><given-names>F</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name><surname>Bosaeus</surname><given-names>I</given-names></string-name>, <string-name><surname>Bruera</surname><given-names>E</given-names></string-name>, <string-name><surname>Fainsinger</surname><given-names>RL</given-names></string-name>, et al. <article-title>Definition and classification of cancer cachexia: an international consensus</article-title>. <source>Lancet Oncol</source><year>2011</year>;<volume>12</volume>:<fpage>489</fpage>–<lpage>495</lpage>.<pub-id pub-id-type="pmid">21296615</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0006"><string-name><surname>Tisdale</surname><given-names>MJ</given-names></string-name>. <article-title>Mechanisms of cancer cachexia</article-title>. <source>Physiol Rev</source><year>2009</year>;<volume>89</volume>:<fpage>381</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">19342610</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0007"><string-name><surname>Esper</surname><given-names>DH</given-names></string-name>, <string-name><surname>Harb</surname><given-names>WA</given-names></string-name>. <article-title>The cancer cachexia syndrome: a review of metabolic and clinical manifestations</article-title>. <source>Nutr Clin Pract</source><year>2005</year>;<volume>20</volume>:<fpage>369</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">16207677</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0008"><string-name><surname>Anderson</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Albrecht</surname><given-names>ED</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>. <article-title>Update on management of cancer‐related cachexia</article-title>. <source>Curr Oncol Rep</source><year>2017</year>;<volume>19</volume>:<fpage>3</fpage>.<pub-id pub-id-type="pmid">28138933</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0009"><string-name><surname>Schloegl</surname><given-names>H</given-names></string-name>, <string-name><surname>Percik</surname><given-names>R</given-names></string-name>, <string-name><surname>Horstmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Villringer</surname><given-names>A</given-names></string-name>, <string-name><surname>Stumvoll</surname><given-names>M</given-names></string-name>. <article-title>Peptide hormones regulating appetite‐focus on neuroimaging studies in humans</article-title>. <source>Diabetes Metab Res Rev</source><year>2011</year>;<volume>27</volume>:<fpage>104</fpage>–<lpage>112</lpage>.<pub-id pub-id-type="pmid">21294236</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0010"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Biller</surname><given-names>BMK</given-names></string-name>, <string-name><surname>Korbonits</surname><given-names>M</given-names></string-name>, <string-name><surname>Popovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Luger</surname><given-names>A</given-names></string-name>, <string-name><surname>Strasburger</surname><given-names>CJ</given-names></string-name>, et al. <article-title>Macimorelin as a diagnostic test for adult GH deficiency</article-title>. <source>J Clin Endocrinol Metab</source><year>2018</year>;<volume>103</volume>:<fpage>3083</fpage>–<lpage>3093</lpage>.<pub-id pub-id-type="pmid">29860473</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0011"><string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Luo</surname><given-names>J</given-names></string-name>, <string-name><surname>Guillory</surname><given-names>B</given-names></string-name>, <string-name><surname>Chen</surname><given-names>JA</given-names></string-name>, <string-name><surname>Zang</surname><given-names>P</given-names></string-name>, <string-name><surname>Yoeli</surname><given-names>JK</given-names></string-name>, et al. <article-title>Ghrelin ameliorates tumor‐induced adipose tissue atrophy and inflammation via Ghrelin receptor‐dependent and ‐independent pathways</article-title>. <source>Oncotarget</source><year>2020</year>;<volume>11</volume>:<fpage>3286</fpage>–<lpage>3302</lpage>.<pub-id pub-id-type="pmid">32934774</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0012"><string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Zang</surname><given-names>P</given-names></string-name>, <string-name><surname>Lee</surname><given-names>B</given-names><suffix>II</suffix></string-name>, <string-name><surname>Anderson</surname><given-names>A</given-names></string-name>, <string-name><surname>Christiani</surname><given-names>LS‐B</given-names></string-name>, et al. <article-title>Growth hormone secretagogue receptor‐1a mediates ghrelin's effects on attenuating tumour‐induced loss of muscle strength but not muscle mass</article-title>. <source>J Cachexia Sarcopenia Muscle</source><year>2021</year>;<volume>12</volume>:<fpage>1280</fpage>–<lpage>1295</lpage>.<pub-id pub-id-type="pmid">34264027</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0013"><string-name><surname>Currow</surname><given-names>D</given-names></string-name>, <string-name><surname>Temel</surname><given-names>JS</given-names></string-name>, <string-name><surname>Abernethy</surname><given-names>A</given-names></string-name>, <string-name><surname>Milanowski</surname><given-names>J</given-names></string-name>, <string-name><surname>Friend</surname><given-names>J</given-names></string-name>, <string-name><surname>Fearon</surname><given-names>KC</given-names></string-name>. <article-title>ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non‐small‐cell lung cancer (NSCLC) patients with cachexia</article-title>. <source>Ann Oncol</source><year>2017</year>;<volume>28</volume>:<fpage>1949</fpage>–<lpage>1956</lpage>.<pub-id pub-id-type="pmid">28472437</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0014"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Boccia</surname><given-names>RV</given-names></string-name>, <string-name><surname>Graham</surname><given-names>CD</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Duus</surname><given-names>EM</given-names></string-name>, <string-name><surname>Allen</surname><given-names>S</given-names></string-name>, et al. <article-title>Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo‐controlled, double‐blind trials</article-title>. <source>Lancet Oncol</source><year>2015</year>;<volume>16</volume>:<fpage>108</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">25524795</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0015"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Friend</surname><given-names>J</given-names></string-name>, <string-name><surname>Allen</surname><given-names>S</given-names></string-name>. <article-title>Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer‐related cachexia: a multicenter, randomized, double‐blind, crossover, pilot study</article-title>. <source>Support Care Cancer</source><year>2013</year>;<volume>21</volume>:<fpage>129</fpage>–<lpage>137</lpage>.<pub-id pub-id-type="pmid">22699302</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0016"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Polvino</surname><given-names>WJ</given-names></string-name>. <article-title>Effect on body weight and safety of RC‐1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo‐controlled, multiple‐dose study in healthy volunteers</article-title>. <source>Oncologist</source><year>2007</year>;<volume>12</volume>:<fpage>594</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">17522248</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0017"><string-name><surname>Katakami</surname><given-names>N</given-names></string-name>, <string-name><surname>Uchino</surname><given-names>J</given-names></string-name>, <string-name><surname>Yokoyama</surname><given-names>T</given-names></string-name>, <string-name><surname>Naito</surname><given-names>T</given-names></string-name>, <string-name><surname>Kondo</surname><given-names>M</given-names></string-name>, <string-name><surname>Yamada</surname><given-names>K</given-names></string-name>, et al. <article-title>Anamorelin (ONO‐7643) for the treatment of patients with non‐small cell lung cancer and cachexia: results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)</article-title>. <source>Cancer</source><year>2018</year>;<volume>124</volume>:<fpage>606</fpage>–<lpage>616</lpage>.<pub-id pub-id-type="pmid">29205286</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0018"><string-name><surname>Takayama</surname><given-names>K</given-names></string-name>, <string-name><surname>Katakami</surname><given-names>N</given-names></string-name>, <string-name><surname>Yokoyama</surname><given-names>T</given-names></string-name>, <string-name><surname>Atagi</surname><given-names>S</given-names></string-name>, <string-name><surname>Yoshimori</surname><given-names>K</given-names></string-name>, <string-name><surname>Kagamu</surname><given-names>H</given-names></string-name>, et al. <article-title>Anamorelin (ONO‐7643) in Japanese patients with non‐small cell lung cancer and cachexia: results of a randomized phase 2 trial</article-title>. <source>Support Care Cancer</source><year>2016</year>;<volume>24</volume>:<fpage>3495</fpage>–<lpage>3505</lpage>.<pub-id pub-id-type="pmid">27005463</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0019"><string-name><surname>Temel</surname><given-names>JS</given-names></string-name>, <string-name><surname>Abernethy</surname><given-names>AP</given-names></string-name>, <string-name><surname>Currow</surname><given-names>DC</given-names></string-name>, <string-name><surname>Friend</surname><given-names>J</given-names></string-name>, <string-name><surname>Duus</surname><given-names>EM</given-names></string-name>, <string-name><surname>Yan</surname><given-names>Y</given-names></string-name>, et al. <article-title>Anamorelin in patients with non‐small‐cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double‐blind, phase 3 trials</article-title>. <source>Lancet Oncol</source><year>2016</year>;<volume>17</volume>:<fpage>519</fpage>–<lpage>531</lpage>.<pub-id pub-id-type="pmid">26906526</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0020"><string-name><surname>Wakabayashi</surname><given-names>H</given-names></string-name>, <string-name><surname>Arai</surname><given-names>H</given-names></string-name>, <string-name><surname>Inui</surname><given-names>A</given-names></string-name>. <article-title>The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers</article-title>. <source>J Cachexia Sarcopenia Muscle</source><year>2021</year>;<volume>12</volume>:<fpage>14</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">33382205</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0021"><string-name><surname>Broglio</surname><given-names>F</given-names></string-name>, <string-name><surname>Boutignon</surname><given-names>F</given-names></string-name>, <string-name><surname>Benso</surname><given-names>A</given-names></string-name>, <string-name><surname>Gottero</surname><given-names>C</given-names></string-name>, <string-name><surname>Prodam</surname><given-names>F</given-names></string-name>, <string-name><surname>Arvat</surname><given-names>E</given-names></string-name>, et al. <article-title>EP1572: a novel peptido‐mimetic GH secretagogue with potent and selective GH‐releasing activity in man</article-title>. <source>J Endocrinol Invest</source><year>2002</year>;<volume>25</volume>: p. RC26‐8.</mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0022"><string-name><surname>Csakvary</surname><given-names>V</given-names></string-name>, <string-name><surname>Ammer</surname><given-names>N</given-names></string-name>, <string-name><surname>Bagci</surname><given-names>EB</given-names></string-name>, <string-name><surname>Bolshova</surname><given-names>OV</given-names></string-name>, <string-name><surname>Damholt</surname><given-names>BB</given-names></string-name>, <string-name><surname>Katanic</surname><given-names>D</given-names></string-name>, et al. <article-title>Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in children with suspected growth hormone deficiency: an open‐label, group comparison, dose‐escalation trial</article-title>. <source>Horm Res Paediatr</source><year>2021</year>;<volume>94</volume>:<fpage>239</fpage>–<lpage>250</lpage>.<pub-id pub-id-type="pmid">34438400</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0023"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Biller</surname><given-names>BMK</given-names></string-name>, <string-name><surname>Korbonits</surname><given-names>M</given-names></string-name>, <string-name><surname>Popovic</surname><given-names>V</given-names></string-name>, <string-name><surname>Luger</surname><given-names>A</given-names></string-name>, <string-name><surname>Strasburger</surname><given-names>CJ</given-names></string-name>, et al. <article-title>Sensitivity and specificity of the macimorelin test for diagnosis of AGHD</article-title>. <source>Endocr Connect</source><year>2021</year>;<volume>10</volume>:<fpage>76</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">33320108</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0024"><string-name><surname>Klaus</surname><given-names>B</given-names></string-name>, <string-name><surname>Sachse</surname><given-names>R</given-names></string-name>, <string-name><surname>Ammer</surname><given-names>N</given-names></string-name>, <string-name><surname>Kelepouris</surname><given-names>N</given-names></string-name>, <string-name><surname>Ostrow</surname><given-names>V</given-names></string-name>. <article-title>Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: results of a single‐dose, randomized controlled study</article-title>. <source>Growth Horm IGF Res</source><year>2020</year>;<volume>52</volume>:<elocation-id>101321</elocation-id>.<pub-id pub-id-type="pmid">32325373</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0025"><string-name><surname>Lissy</surname><given-names>M</given-names></string-name>, <string-name><surname>Demmel</surname><given-names>V</given-names></string-name>, <string-name><surname>Sachse</surname><given-names>R</given-names></string-name>, <string-name><surname>Ammer</surname><given-names>N</given-names></string-name>, <string-name><surname>Kelepouris</surname><given-names>N</given-names></string-name>, <string-name><surname>Ostrow</surname><given-names>V</given-names></string-name>. <article-title>Thorough QT/QTc study evaluating the effect of macimorelin on cardiac safety parameters in healthy participants</article-title>. <source>Clin Pharmacol Drug Dev</source><year>2021</year>;<volume>10</volume>:<fpage>494</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">32961034</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0026"><string-name><surname>MacLean</surname><given-names>CM</given-names></string-name>, <string-name><surname>Casanova</surname><given-names>AT</given-names></string-name>, <string-name><surname>Baselgia‐Jeker</surname><given-names>L</given-names></string-name>, <string-name><surname>Neave</surname><given-names>N</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>F</given-names></string-name>, <string-name><surname>Skillern</surname><given-names>L</given-names></string-name>, et al. <article-title>Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD‐07) in healthy subjects</article-title>. <source>J Clin Pharmacol</source><year>2009</year>;<volume>49</volume>:<fpage>553</fpage>–<lpage>559</lpage>.<pub-id pub-id-type="pmid">19293342</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0027"><string-name><surname>Piccoli</surname><given-names>F</given-names></string-name>, <string-name><surname>Degen</surname><given-names>L</given-names></string-name>, <string-name><surname>MacLean</surname><given-names>C</given-names></string-name>, <string-name><surname>Peter</surname><given-names>S</given-names></string-name>, <string-name><surname>Baselgia</surname><given-names>L</given-names></string-name>, <string-name><surname>Larsen</surname><given-names>F</given-names></string-name>, et al. <article-title>Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects</article-title>. <source>J Clin Endocrinol Metab</source><year>2007</year>;<volume>92</volume>:<fpage>1814</fpage>–<lpage>1820</lpage>.<pub-id pub-id-type="pmid">17284637</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0028"><string-name><surname>Sailer</surname><given-names>CO</given-names></string-name>, <string-name><surname>Winzeler</surname><given-names>B</given-names></string-name>, <string-name><surname>Urwyler</surname><given-names>SA</given-names></string-name>, <string-name><surname>Schnyder</surname><given-names>I</given-names></string-name>, <string-name><surname>Refardt</surname><given-names>J</given-names></string-name>, <string-name><surname>Eckert</surname><given-names>A</given-names></string-name>, et al. <article-title>Oxytocin levels in response to pituitary provocation tests in healthy volunteers</article-title>. <source>Eur J Endocrinol</source><year>2021</year>;<volume>185</volume>:<fpage>355</fpage>–<lpage>364</lpage>.<pub-id pub-id-type="pmid">34181566</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0029"><string-name><surname>Urwyler</surname><given-names>SA</given-names></string-name>, <string-name><surname>Lustenberger</surname><given-names>S</given-names></string-name>, <string-name><surname>Drummond</surname><given-names>JR</given-names></string-name>, <string-name><surname>Soares</surname><given-names>BS</given-names></string-name>, <string-name><surname>Vogt</surname><given-names>DR</given-names></string-name>, <string-name><surname>Ammer</surname><given-names>N</given-names></string-name>, et al. <article-title>Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers</article-title>. <source>Pituitary</source><year>2021</year>;<volume>24</volume>:<fpage>555</fpage>–<lpage>563</lpage>.<pub-id pub-id-type="pmid">33615399</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0030"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Swerdloff</surname><given-names>R</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Kyle</surname><given-names>M</given-names></string-name>, <string-name><surname>Kipnes</surname><given-names>M</given-names></string-name>, <string-name><surname>Biller</surname><given-names>BM</given-names></string-name>, et al. <article-title>Macimorelin (AEZS‐130)‐stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency</article-title>. <source>J Clin Endocrinol Metab</source><year>2013</year>;<volume>98</volume>:<fpage>2422</fpage>–<lpage>2429</lpage>.<pub-id pub-id-type="pmid">23559086</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0031"><string-name><surname>Feinstein</surname><given-names>AR</given-names></string-name>. <article-title>Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis</article-title>. <source>JAMA</source><year>1964</year>;<volume>189</volume>. <pub-id pub-id-type="doi">10.1001/jama.1964.03070110071036</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0032"><string-name><surname>Bidlingmaier</surname><given-names>M</given-names></string-name>, <string-name><surname>Friedrich</surname><given-names>N</given-names></string-name>, <string-name><surname>Emeny</surname><given-names>RT</given-names></string-name>, <string-name><surname>Spranger</surname><given-names>J</given-names></string-name>, <string-name><surname>Wolthers</surname><given-names>OD</given-names></string-name>, <string-name><surname>Roswall</surname><given-names>J</given-names></string-name>, et al. <article-title>Reference intervals for insulin‐like growth factor‐1 (IGF‐I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF‐I immunoassay conforming to recent international recommendations</article-title>. <source>J Clin Endocrinol Metab</source><year>2014</year>;<volume>99</volume>:<fpage>1712</fpage>–<lpage>1721</lpage>.<pub-id pub-id-type="pmid">24606072</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0033"><string-name><surname>Palmer</surname><given-names>JL</given-names></string-name>, <string-name><surname>Fisch</surname><given-names>MJ</given-names></string-name>. <article-title>Association between symptom distress and survival in outpatients seen in a palliative care cancer center</article-title>. <source>J Pain Symptom Manage</source><year>2005</year>;<volume>29</volume>:<fpage>565</fpage>–<lpage>571</lpage>.<pub-id pub-id-type="pmid">15963865</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0034"><string-name><surname>Bauer</surname><given-names>JD</given-names></string-name>, <string-name><surname>Capra</surname><given-names>S</given-names></string-name>. <article-title>Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy? A pilot study</article-title>. <source>Support Care Cancer</source><year>2005</year>;<volume>13</volume>:<fpage>270</fpage>–<lpage>274</lpage>.<pub-id pub-id-type="pmid">15583950</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0035"><string-name><surname>Anderson</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Mallen</surname><given-names>MC</given-names></string-name>, <string-name><surname>Migula</surname><given-names>D</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Wu</surname><given-names>PC</given-names></string-name>, et al. <article-title>Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients</article-title>. <source>Clin Nutr</source><year>2021</year>;<volume>40</volume>:<fpage>978</fpage>–<lpage>986</lpage>.<pub-id pub-id-type="pmid">32713720</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0036"><string-name><surname>Crown</surname><given-names>AL</given-names></string-name>, <string-name><surname>Cottle</surname><given-names>K</given-names></string-name>, <string-name><surname>Lightman</surname><given-names>SL</given-names></string-name>, <string-name><surname>Falk</surname><given-names>S</given-names></string-name>, <string-name><surname>Mohamed‐Ali</surname><given-names>V</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>L</given-names></string-name>, et al. <article-title>What is the role of the insulin‐like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated?</article-title><source>Clin Endocrinol (Oxf)</source><year>2002</year>;<volume>56</volume>:<fpage>723</fpage>–<lpage>733</lpage>.<pub-id pub-id-type="pmid">12072041</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0037"><string-name><surname>Garcia</surname><given-names>JM</given-names></string-name>, <string-name><surname>Garcia‐Touza</surname><given-names>M</given-names></string-name>, <string-name><surname>Hijazi</surname><given-names>RA</given-names></string-name>, <string-name><surname>Taffet</surname><given-names>G</given-names></string-name>, <string-name><surname>Epner</surname><given-names>D</given-names></string-name>, <string-name><surname>Mann</surname><given-names>D</given-names></string-name>, et al. <article-title>Active ghrelin levels and active to total ghrelin ratio in cancer‐induced cachexia</article-title>. <source>J Clin Endocrinol Metab</source><year>2005</year>;<volume>90</volume>:<fpage>2920</fpage>–<lpage>2926</lpage>.<pub-id pub-id-type="pmid">15713718</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0038"><string-name><surname>Hiura</surname><given-names>Y</given-names></string-name>, <string-name><surname>Takiguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Yamamoto</surname><given-names>K</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>T</given-names></string-name>, <string-name><surname>Kurokawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yamasaki</surname><given-names>M</given-names></string-name>, et al. <article-title>Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo‐controlled phase 2 study</article-title>. <source>Cancer</source><year>2012</year>;<volume>118</volume>:<fpage>4785</fpage>–<lpage>4794</lpage>.<pub-id pub-id-type="pmid">22282373</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0039"><string-name><surname>Neary</surname><given-names>NM</given-names></string-name>, <string-name><surname>Small</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Wren</surname><given-names>AM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JL</given-names></string-name>, <string-name><surname>Druce</surname><given-names>MR</given-names></string-name>, <string-name><surname>Palmieri</surname><given-names>C</given-names></string-name>, et al. <article-title>Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo‐controlled trial</article-title>. <source>J Clin Endocrinol Metab</source><year>2004</year>;<volume>89</volume>:<fpage>2832</fpage>–<lpage>2836</lpage>.<pub-id pub-id-type="pmid">15181065</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0040"><string-name><surname>Molitch</surname><given-names>ME</given-names></string-name>, <string-name><surname>Clemmons</surname><given-names>DR</given-names></string-name>, <string-name><surname>Malozowski</surname><given-names>S</given-names></string-name>, <string-name><surname>Merriam</surname><given-names>GR</given-names></string-name>, <string-name><surname>Vance</surname><given-names>ML</given-names></string-name>, <string-name><surname>Endocrine</surname><given-names>S</given-names></string-name>. <article-title>Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source><year>2011</year>;<volume>96</volume>:<fpage>1587</fpage>–<lpage>1609</lpage>.<pub-id pub-id-type="pmid">21602453</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0041"><string-name><surname>Bermann</surname><given-names>M</given-names></string-name>, <string-name><surname>Jaffe</surname><given-names>CA</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>W</given-names></string-name>, <string-name><surname>DeMott‐Friberg</surname><given-names>R</given-names></string-name>, <string-name><surname>Barkan</surname><given-names>AL</given-names></string-name>. <article-title>Negative feedback regulation of pulsatile growth hormone secretion by insulin‐like growth factor I. Involvement of hypothalamic somatostatin</article-title>. <source>J Clin Invest</source><year>1994</year>;<volume>94</volume>:<fpage>138</fpage>–<lpage>145</lpage>.<pub-id pub-id-type="pmid">7913710</pub-id></mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0042"><string-name><surname>Wheelwright</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Darlington</surname><given-names>AS</given-names></string-name>, <string-name><surname>Hopkinson</surname><given-names>JB</given-names></string-name>, <string-name><surname>Fitzsimmons</surname><given-names>D</given-names></string-name>, <string-name><surname>White</surname><given-names>A</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>CD</given-names></string-name>. <article-title>A systematic review to establish health‐related quality‐of‐life domains for intervention targets in cancer cachexia</article-title>. <source>BMJ Support Palliat Care</source><year>2016</year>;<volume>6</volume>:<fpage>307</fpage>–<lpage>314</lpage>.</mixed-citation>
              </ref>
              <ref id="jcsm13191-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="jcsm13191-cit-0043"><string-name><surname>von Haehling</surname><given-names>S</given-names></string-name>, <string-name><surname>Morley</surname><given-names>JE</given-names></string-name>, <string-name><surname>Coats</surname><given-names>AJS</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>. <article-title>Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021</article-title>. <source>J Cachexia Sarcopenia Muscle</source><year>2021</year>;<volume>12</volume>:<fpage>2259</fpage>–<lpage>2261</lpage>.<pub-id pub-id-type="pmid">34904399</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
